Evidence map›Paper›PMID 41290664›Full record

ArticleNature communications2025

The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes.

Henrik Lilljebjörn, Pablo Peña-Martínez, Hanna Thorsson, Rasmus Henningsson, Marianne Rissler, Niklas Landberg, Noelia Puente-Moncada, Sofia von Palffy, Vendela Rissler, Petr Stanek and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Two Decades ofCancers · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Henrik LilljebjörnDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. henrik.lilljebjorn@med.lu.se.ORCID http://orcid.org/0000-0001-8703-1173
Pablo Peña-MartínezDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0789-6431
Hanna ThorssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-5393-2942
Rasmus HenningssonDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Marianne RisslerDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Niklas LandbergDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-6752-6507
Noelia Puente-MoncadaDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Sofia von PalffyDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-5640-4037
Vendela RisslerDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Petr StanekDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0003-6856-8575
Jonathan DespondsInstitut Roche, Boulogne-Billancourt, France.ORCID http://orcid.org/0000-0001-7112-3217
Xiangfu ZhongDepartment of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden.ORCID http://orcid.org/0000-0002-1872-1186
Gunnar JuliussonDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Vladimir LazarevicDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-1782-4423
Sören LehmannDepartment of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden.
Magnus FontesInstitut Roche, Boulogne-Billancourt, France.
Helena ÅgerstamDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Carl SandénDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-8931-9565
Christina Orsmark-PietrasDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-6533-0305
Thoas FioretosDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden. thoas.fioretos@med.lu.se.ORCID http://orcid.org/0000-0002-3235-6154

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2023-0097Cancerfonden (Swedish Cancer Society) 23-2953 PJ 01Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) 2022-0232Vetenskapsrådet (Swedish Research Council) 2023-02376
6 · The paper itself

Abstract

Acute myeloid leukemia is a genetically and cellularly heterogeneous disease. We characterize 120 AMLs using genomic and transcriptomic analyses, including single-cell RNA sequencing. Our results reveal an extensive cellular heterogeneity that distorts the bulk transcriptomic profiles. Selective examination of the transcriptional signatures of >90,000 immature AML cells identifies four main clusters, thereby extending current genomic classification of AML. Notably, NPM1-mutated AML can be stratified into two clinically relevant classes, with NPM1

Indexed as

Immune EvasionLeukemia, Myeloid, AcuteNuclear ProteinsAdultAgedFemaleGene Expression ProfilingHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMutationNucleophosminSingle-Cell AnalysisT-LymphocytesTranscriptomeNPM1 protein, humanNuclear ProteinsNucleophosmin

Identifiers

PMID41290664
PMCPMC12658069

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.